NYSE TURNAROUNDS

Struggle: Down 54% over past year. Q4 2025 showed 94.6% medical cost ratio. Market panicked on Medicaid uncertainty.

Catalyst Details: Medicaid re-enrollment began in Q1 2026. Company beat earnings expectations. Cost controls are structural, not one-time. Guidance raised for full year.

Bull Case: $310B healthcare giant with diversified revenue. Medicaid = 35% of revenue. Cost controls are structural wins, not temporary. Medical loss ratios normalizing.

What Could Break This: Political uncertainty on Medicaid policy remains real. ACA changes could impact enrollment. Medical cost trends could reaccelerate if underlying healthcare inflation persists.

Key Statistics:

• Years Struggling: 5
• Distance from ATH: -41.7%
• Distance from ATL: +50.4%

Sources: Molina Healthcare Investor Relations | SEC EDGAR

Struggle: Fell from $213 to $83 as post-COVID e-commerce boom reversed. Revenue growth weak. Stock down 49% from highs.

Catalyst Details: Q1 2026: Revenue $21.2B (-1.6% YoY), but ARPU +7.7%. Operating profit $1.27B. Healthcare logistics hit record $3B. CEO Kelly Ortberg reaffirmed full-year guidance: $89.7B revenue, 9.6% operating margin, EPS flat to 2025. $3B cost-out program on track. Expects margin expansion in Q2 and H2.

Current Status (Jun 8): Stock at $108.34, +0.3% from entry. Stock is flat because Amazon volume loss is real near-term headwind. BUT restructuring is measurable and credible. Management discipline evident. Expect acceleration once volume stabilizes in H2 2026.

Bull Case: $108 is well below 5-year average. Recovery toward $150 still below historical highs. Durable logistics franchise with global reach. Amazon glide-down is temporary; healthcare logistics is secular growth driver. Supply Chain Solutions segment growing high single-digits.

Risk Alert: E-commerce growth may not return to post-COVID levels. Macro slowdown could hurt volume further. But management has clear cost targets and is executing.

Key Statistics:

• Years Struggling: 4
• Distance from ATH: -11.5%
• Distance from ATL: +31.7%

Sources: UPS Investor Relations | SEC EDGAR | TipRanks Earnings Summary

Struggle: Down 47%+ from Nov 2024 high on government budget cut fears under DOGE mandate.

Catalyst Details: Federal AI modernization cross-functional team mandate from White House. Pentagon AI spending increasing. $38B backlog of contracts. Defense IT contracting resilient across budget cycles.

Bull Case: $38B backlog provides 2+ years of revenue visibility. Federal AI modernization is secular driver independent of budget politics. Defense IT contracting is durable. $1.5T in government IT modernization push.

What Could Break This: Regulatory changes could impact contract volume. DOGE budget cuts could extend longer than expected. Competition for contracts intensifies.

Key Statistics:

• Years Struggling: 1.5
• Distance from ATH: -42.3%
• Distance from ATL: +8.7%

Sources: Booz Allen Investor Relations | Department of Defense | SEC EDGAR

Struggle: Fell from $100+ to mid-$40s. Rising insurer costs, pharmacy margin compression, integration challenges.

Catalyst Details: Q1 2026 (May 6): Beat estimates on all metrics. EPS $2.57 vs $2.21 consensus (+16%). Revenue $100.43B up 6.2% YoY. CEO Joyner's restructuring working. Management raised FY guidance to $7.30–$7.50 EPS (from $7.00–$7.20).

Current Status (Jun 8): Stock at $95.85, up +27.8% from $75 entry. Approaching lower target of $98. Aetna recovery is real and durable. Medical Loss Ratio improving. Morgan Stanley raised PT to $111; Truist raised to $108. Next catalyst: Q2 earnings (late July)—watch for medical cost trends.

Bull Case: At 11x forward earnings, priced for distress that's no longer materializing. Optum integration benefits still to come. $310B+ company with diversified revenue streams. Restructuring credible.

Risk Alert: Medical cost trends could reaccelerate. If Q2 shows deterioration in MBR, thesis breaks. Stock is approaching target—consider trimming at $100+.

Key Statistics:

• Years Struggling: 3
• Distance from ATH: -2.0%
• Distance from ATL: +62.7%

Sources: CVS Health Investor Relations | SEC EDGAR | CNBC Q1 Report

Struggle: Down 37% in 2025 on Medicaid/ACA uncertainty from Republican policy shifts.

Catalyst Details: Q1 2026 adj. EPS of $3.37 was $0.50 above guidance. Earnings resilience proves model strength even with policy uncertainty.

Bull Case: Even with policy uncertainty, Q1 beat shows earnings power. Medicaid represents stable revenue base. Cost controls working. $30B+ annual revenue.

What Could Break This: Medicaid policy risk is real and ongoing. ACA uncertainty persists. Major regulatory change could impact economics significantly.

Key Statistics:

• Years Struggling: 3
• Distance from ATH: -46%
• Distance from ATL: +38%

Sources: Centene Investor Relations | SEC EDGAR

Struggle: Offshore drillers endured years of pain as oil majors slashed exploration budgets post-COVID. Stock down 60%+ from highs.

Catalyst Details: Already in recovery mode. Positive Venezuela drilling developments unlocked new offshore projects. New contracts being awarded.

Bull Case: Offshore rig supply structurally constrained. New drillships take years to build. Supply/demand imbalance is durable. $1B+ backlog.

What Could Break This: Oil price volatility could impact demand. Geopolitical risk on Venezuela could change suddenly. Contract delays possible.

Key Statistics:

• Years Struggling: 7
• Distance from ATH: -14.5%
• Distance from ATL: +88%

Sources: Noble Corporation Investor Relations | SEC EDGAR

Struggle: Sustained downtrend throughout 2024 and early 2025 as energy services cycle weakened.

Catalyst Details: Rounding bottom accumulation pattern forming. Rising buyer interest emerging in Q3–Q4 2025. Technical setup improving.

Bull Case: Energy services cycles are timing-dependent, not secular. Accumulation pattern suggests institutional buying. Lower-risk energy recovery play with technical confirmation.

What Could Break This: Energy services cycles can be prolonged. Earnings visibility limited. Energy prices could decline further.

Key Statistics:

• Years Struggling: 1
• Distance from ATH: -17.9%
• Distance from ATL: +64.3%

Sources: SEC EDGAR

Struggle: Teladoc was pandemic darling that cratered as in-person care resumed. Down 80%+ over five years. $13.7B goodwill impairment taken.

Catalyst Details: Market prices in near-total failure despite company still operating legitimate telemedicine business. At $9, significant discount to any recovery scenario.

Bull Case: At $9, market expects bankruptcy. Partial recovery toward $18 is achievable if business stabilizes. Asymmetric risk/reward for patient investors. Telemedicine remains viable business model.

What Could Break This: Business model could deteriorate further. Bankruptcy possible. Cash burn could accelerate. Telehealth adoption could stall.

Key Statistics:

• Years Struggling: 6
• Distance from ATH: -28.3%
• Distance from ATL: +59.1%

Sources: Teladoc Investor Relations | SEC EDGAR

⚠️ THESIS BREAKING — RECOMMEND REMOVAL

What Happened: NKE thesis was "CEO Hill's Win Now restructuring + inventory cleanup." This no longer applies. Data from June 5-8 shows China weakness is STRUCTURAL, not cyclical.

Struggle: At 11-year low, down 76% off all-time high. North America wholesale weakness. China recovery stalling.

Q4 2025 Reality (reported March 2026): EPS beat ($0.35 vs $0.29). Revenue $11.28B beat. BUT: Management guided Q4 FY2026 revenue -2% to -4% YoY. Greater China revenue expected to fall ~20%. This was major shock.

Current Status (Jun 8): Stock at $42.98, DOWN 2.3% from $44 entry. Below 50-day SMA (bearish signal). Below 200-day SMA (long-term downtrend). Goldman Sachs downgraded Buy → Neutral, cut PT to $52 (vs prior $76). Analyst consensus PT is $60.49 with HUGE range ($23–$120), signaling uncertainty.

Why Thesis is Breaking: Greater China is not coming back in 12 months. Tariff headwinds persist. Inventory cleanup taking 2+ years. Margin recovery timeline extended 12–24 months. This turnaround is NOT the 6–12 month asymmetric opportunity we identified.

Key Statistics:

• Years Struggling: 4
• Distance from ATH: -45%
• Distance from ATL: +7.3% (near lows!)
• Current return from entry: -2.3%

Recommendation: REMOVE from portfolio. Stock is not performing. Thesis timeline has extended to 2+ years. Opportunity cost too high. Replace with fresher turnaround catalyst.

Sources: Nike Investor Relations | SEC EDGAR | TIKR Analysis | Simply Wall St

Struggle: Spent 2 years fighting Medicare Advantage cost inflation. Medical loss ratios surged. Stock stagnated as investors questioned cost management.

Catalyst Details: Q1 beat $2.1B over consensus. Prior authorization elimination announced (70% by end 2026). Dr. Scott Gottlieb (ex-FDA Commissioner) joins board as independent voice.

Bull Case: $310B healthcare giant with diversified Optum services division ($24B operating earnings). Q1 beat proves cost controls working. Gottlieb board seat signals governance credibility and outside validation.

What Could Break This: Medicare policy could shift against insurers. Cost trends could reaccelerate. Stock could consolidate before next move higher.

Key Statistics:

• Years Struggling: 2
• Distance from ATH: -1.7%
• Distance from ATL: +69%

Sources: UnitedHealth Investor Relations | SEC EDGAR

Struggle: SaaSpocalypse panic hit in Feb 2026. Stock fell 62% from $211 to $89 on fears AI agents would disrupt SaaS model.

Catalyst Details: Q1 beat every metric. CEO raised 2026 AI revenue target from $1B to $1.5B (+50%). Knowledge 2026 conference delivered ServiceNow Otto product announcement to market validation.

Bull Case: Now Assist showing customers spending $1M+ growing 130% YoY. 97% renewal rate (highest in industry). Market is pricing AI disruption while company is winning at AI. Asymmetric upside.

What Could Break This: If Q2 results disappoint or enterprise IT budgets pull back, stock could consolidate longer. But momentum appears genuine.

Key Statistics:

• Years Struggling: 3
• Distance from ATH: -46.4%
• Distance from ATL: +39.5%

Sources: ServiceNow Investor Relations | SEC EDGAR

Struggle: SaaSpocalypse fears extended to security sector. Stock traded $70s–$80s on worries hardware-centric model would face disruption.

Catalyst Details: Q1 2026 beat: Billings +31% YoY. Product revenue +41% YoY. OT billings +70%. AI-driven security operations +23%. BofA raised to $130. Arete reversed from Sell to Buy.

Bull Case: AI is expanding security budget, not cannibalizing it. FortiGate appliances still core infrastructure. $7.35B deferred revenue provides visibility. 31% billings growth proves durable demand.

What Could Break This: If AI spending cycle cools, could see pullback. Hardware cycle could extend longer than expected.

Key Statistics:

• Years Struggling: 2
• Distance from ATH: -0.7%
• Distance from ATL: +112%

Sources: Fortinet Investor Relations | SEC EDGAR

Struggle: SaaSpocalypse panic crushed stock 30% YTD. Market feared AI agents would disrupt seat-based SaaS model. Stock hit 3-year lows near $170.

Catalyst Details: Feb 25 Q4 beat EPS by 41% ($3.81 vs $2.69). Revenue $11.2B up 12% YoY. Agentforce generating $800M ARR (buried in footnotes). May 27 earnings will break out AI revenue explicitly.

Bull Case: World's leading CRM with 100,000+ customers. $54B contracted future revenue (cRPO). At $170 = 12x forward earnings. $25B buyback (5% of market cap annually). Analyst consensus $338 (99% upside).

What Could Break This: If May 27 results disappoint on AI monetization, stock could consolidate. But execution probability is very high based on Q4 beat.

Key Statistics:

• Years Struggling: 2
• Distance from ATH: -33.6%
• Distance from ATL: +12.2%

Sources: Salesforce Investor Relations | SEC EDGAR

Struggle: Stock down 40% in 2026 on regulatory concerns. UK, Australia pushing child safety rules. New Mexico lawsuit filed. Market panicked on regulation risk.

Catalyst Details: May 6 Q1 beat: EPS -$0.05 vs -$0.07 expected. SMB spend +30% YoY. Subscriptions (Snapchat+) +87% to $285M. Gross margins expanded to 57% (targeting 60%+).

Bull Case: Upfront ad commitments (leading indicator) up 10% YoY. Regulatory concerns are real but clearing might trigger 33–50% rebound. Conservative upside is clear; binary regulatory risk is real.

What Could Break This: Major regulatory crackdown could crush user growth. Advertiser spend could pull back on platform safety concerns.

Key Statistics:

• Years Struggling: 8
• Distance from ATH: -42.4%
• Distance from ATL: +51.3%

Sources: Snap Investor Relations | SEC EDGAR

Struggle: 2022–2024 collapse. Market share lost to larger retailers. Same-store sales weak. 3-year turnaround under Vasos just beginning.

Catalyst Details: Q1 2026 beat on EPS (June 6). Market down 3% despite beat because same-store sales only +2% YoY (less than inflation). But execution quality is improving.

Bull Case: Market is being too harsh punishing one quarter. Gross margins improving. Inventory optimizing. Beat after years of missing = execution quality improving. Could launch 20–30% gains once market stops punishing misses.

What Could Break This: Retail cycles can be prolonged. Consumer discretionary weakness could persist. Turnaround could stall.

Key Statistics:

• Years Struggling: 3
• Distance from ATH: -34.2%
• Distance from ATL: +9.5%

Sources: Dollar General Investor Relations | SEC EDGAR

Struggle: Department stores written off by market. Falling from $100+ to current levels. Narrative: "Retail is dead."

Catalyst Details: June 3 Q1 2026 beat. Strongest comp sales in 4 years. CEO Tony Spring 2 years into 3-year turnaround. Closing bad stores, reinvesting in winners. Strategy is working.

Bull Case: Lower-risk than DG. Q1 beat proves strategy working. Dividend 4.3% (safe and growing). As Q2/Q3/Q4 beat, narrative shifts from "dying" to "recovering." Patience = 20–40% gains.

What Could Break This: Retail sector risk persists. Consumer discretionary weakness could continue. Competition could intensify.

Key Statistics:

• Years Struggling: 15
• Distance from ATH: -9.9%
• Distance from ATL: +109%

Sources: Macy's Investor Relations | SEC EDGAR